Primary brain tumours in adults

Lancet

Volumn 361, Issue 9354, 2003, Pages 323-331

  Behin, Anthony ^a   Hoang Xuan, Khe ^a   Carpentier, Antoine F ^a   Delattre, Jean Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ETOPOSIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPHENIDATE; PROCARBAZINE; STEROID; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE;

ASTROCYTOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; IMMUNOCOMPETENCE; LYMPHOMA; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SIDE EFFECT; TREATMENT PLANNING;

EID: 0037464792     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12328-8     Document Type: Review

References (95)

1. Legler J.M., Gloeckler Ries L.A., Smith M.A., et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 91:1999;2050A-2051A.
2. Kleihues P., Cavenee W.K. Pathology and genetics of tumours of the nervous system. 2000;IARC Press, Lyon.
3. He J., Mokhtari K., Sanson M., et al. Glioblastoma with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 60:2001;863-871.
4. Daumas-Duport C., Varlet P., Tucker M.L., Beuvon F., Cervera P., Chodkiewicz J.P. Oligodendrogliomas, part I: patterns of growth, histological diagnosis, clinical and imaging correlations-a study of 153 cases. J Neurooncol. 34:1997;37-59.
5. Fortin D., Cairncross G., Hammond R.R. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 45:1999;1279-1291.
6. Burger P.C. What is an oligodendroglioma? Brain Pathol. 12:2002;257-259.
7. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 79:1997;1381-1393.
8. Sasaki H., Zlatescu M.C., Betensky R.A., et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma" J Neuropathol Exp Neurol. 61:2002;58-63.
9. Marie Y., Sanson M., Mokhtari K., et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet. 358:2001;298-300.
10. Maher E.A., Furnari F.B., Bachoo R.M., et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:2001;1311-1333.
11. Ichimura K., Schmidt E.E., Goike H.M., Collins V.P. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene. 13:1996;1065-1072.
12. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6:1996;217-223.
13. Zhou X.P., Li Y.J., Hoang-Xuan K., et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer. 84:1999;150-154.
14. Reifenberger J., Reifenberger G., Liu L., James C.D., Wechsler W., Collins V.P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 145:1994;1175-1190.
15. Hoang-Xuan K., He J., Huguet S., et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 57:2001;1278-1281.
16. Zlatescu M.C., TehraniYazdi A., Sasaki H., et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61:2001;6713-6715.
17. Maintz D., Fiedler K., Koopmann J., et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 56:1997;1098-1104.
18. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2:2001;120-129.
19. Scott C.B., Scarantino C., Urtasun R., et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 40:1998;51-55.
20. Bauman G., Lote K., Larson D., et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 45:1999;923-929.
21. Pignatti F., van den Bent M., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 20:2002;2076-2084.
22. Olson J.D., Riedel E., DeAngelis L.M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 54:2000;1442-1448.
23. Ricci P.E., Dungan D.H. Imaging of low- and intermediate grade gliomas. Semin Radiat Oncol. 11:2001;103-112.
24. Ribom D., Eriksson A., Hartman M., et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 92:2001;1541-1549.
25. Capelle L., Mandonnet E., Broet P., et al. Linear growth of mean tumor diameter in WHO grade II gliomas. Neurology. 58:(suppl):2002;A13.
26. Keles G.E., Lamborn K.R., Berger M.S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 95:2001;735-745.
27. Matz P.G., Cobbs C., Berger M.S. Intraoperative cortical mapping as a guide to the surgical resection of gliomas. J Neurooncol. 42:1999;233-245.
28. Bauman G., Pahapill P., Macdonald D., Fisher B., Leighton C., Cairncross J.G. Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci. 26:1999;18-22.
29. Karim A.B., Afra D., Cornu P., et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4-an interim analysis. Int J Radiat Oncol Biol Phys. 52:2002;316-324.
30. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 20:2002;2267-2276.
31. Vigliani M.C., Sichez N., Poisson M., Delattre J.Y. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys. 35:1996;527-533.
32. Mason W.P., Krol G.S., DeAngelis L.M. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 46:1996;203-207.
33. Soffietti R., Ruda R., Bradac G.B., Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 43:1998;1066-1073.
34. DeAngelis L.M. Brain tumors. N Engl J Med. 344:2001;114-123.
35. Weller M., Schmidt C., Roth W., Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology. 48:1997;1704-1709.
36. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 54:2000;1886-1893.
37. Zamboni W.C., Gajjar A.J., Heideman R.L., et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 4:1998;783-789.
38. Marras L.C., Geerts W.H., Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 89:2000;640-646.
39. Meyers C.A., Weitzner M.A., Valentine A.D., Levin V.A. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 16:1998;2522-2527.
40. Mukand J.A., Blackinton D.D., Crincoli M.G., Lee J.J., Santos B.B. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil. 80:2001;346-350.
41. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol. 42:1999;303-305.
42. Walker M.D., Alexander E. Jr, Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 49:1978;333-343.
43. Vigliani M.C., Duyckaerts C., Delattre J.Y. Radiation-induced cognitive dysfunction in adults. Vecht C.J. Handbook of clinical neurology. 23:1997;371-388 Elsevier Science, Amsterdam.
44. Chadha M., Capala J., Coderre J.A., et al. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys. 40:1998;829-834.
45. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 71:1989;1-9.
46. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 19:2001;509-518.
47. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:2002;1011-1018.
48. Ino Y., Zlatescu M.C., Sasaki H., et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 92:2000;983-990.
49. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:2000;1350-1354.
50. Westphal M., Daumas-Duport C., Thoron L., Hilt D., Olivares R., Delavault P. Gliadel® (polifeprosan 20 with carmustine 3·85% implant): a multinational phase III randomized double-blind trial in newly-diagnosed malignant glioma. Proc Annu Meet Am Soc Clin Oncol. 18:1999;A594.
51. Wallner K.E., Galicich J.H., Krol G., Arbit E., Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 16:1989;1405-1409.
52. Brandes A.A., Vastola F., Monfardini S. Reoperation in recurrent high-grade gliomas. Am J Clin Oncol. 22:1999;387-390.
53. Hudes R.S., Corn B.W., Werner-Wasik M., et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 43:1999;293-298.
54. Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol. 17:1999;2762-2771.
55. Friedman H.S., Pluda J., Quinn J.A., et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 18:2000;3522-3528.
56. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 11:2000;2389-2401.
57. Daumas-Duport C., Tucker M.L., Kolles H., et al. Oligodendrogliomas, part II: a new grading system based on morphological and imaging criteria. J Neurooncol. 34:1997;61-78.
58. Cairncross J.G., Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 23:1988;360-364.
59. Kyritsis A.P., Yung W.K., Bruner J., Gleason M.J., Levin V.A. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery. 32:1993;365-370.
60. Van den Bent M.J., Kros J.M., Heimans J.J., et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 51:1998;1140-1145.
61. Chinot O.L., Honoré S., Dufour H., et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 19:2001;2449-2455.
62. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglioma. J Natl Cancer Inst. 90:1998;1473-1479.
63. Ino Y., Betensky R.A., Zlatescu M.C., et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 7:2001;839-845.
64. Kim L., Hochberg F.H., Thornton A.F., et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg. 85:1996;602-607.
65. Coté T.R., Manns A., Hardy C.R., Yelin F.J., Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst. 88:1996;675-679.
66. Corn B.W., Marcus S.M., Topham A., Hauck W., Curran W.J. Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer. 79:1997;2409-2413.
67. Fine H.A., Mayer R.J. Primary central nervous system lymphoma. Ann Intern Med. 119:1993;1093-1104.
68. Camilleri-Broët S., Martin A., Moreau A., et al. Primary central nervous system lymphoma in 72 immunocompetent patients: Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 110:1998;607-612.
69. Balmaceda C., Gaynor J.J., Sun M., Gluck J.T., DeAngelis L.M. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance and implications. Ann Neurol. 38:1995;202-209.
70. Peterson K., Gordon K.B., Heinemann M.H., DeAngelis L.M. The clinical spectrum of ocular lymphoma. Cancer. 72:1993;843-849.
71. Herrlinger U. Primary CNS lymphoma: findings outside the brain. J Neurooncol. 43:1999;227-230.
72. Nelson D.F. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 43:1999;241-247.
73. Nelson D.F., Martz K., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 23:1992;9-17.
74. Blay J.Y., Conroy T., Chevreau C., et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 16:1998;864-871.
75. Lachance D.H., Brizel D.M., Gockerman J.P., et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary centr al nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology. 44:1994;1721-1727.
76. O'Neill B.P., O'Fallon J.R., Earle J.D., Colgan J.P., Brown L.D., Krigel R.L. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys. 33:1995;663-673.
77. Schultz C., Scott C., Sherman W., et al. Preirradiation chemotherap y with cyclophosphamide, doxorubicin, vincristine and dexamethasone for primary CNS lymphomas: initial report of the radiation therapy oncology group protocol 88-06. J Clin Oncol. 14:1996;556-564.
78. Gabbai A.A., Hochberg F.H., Linggood R.M., Bashir R., Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma: report of 13 cases. J Neurosurg. 70:1989;190-194.
79. DeAngelis L.M., Yahalom J., Thaler H.T., Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 10:1992;635-643.
80. Glass J., Gruber M.L., Cher L., Hochberg F. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 81:1994;188-195.
81. Glass J., Shustik C., Hochberg F., Cher L., Gruber M.L. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol. 30:1996;257-265.
82. Blay J.Y., Bouhour D., Carrie C., et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood. 86:1995;2922-2929.
83. Brada M., Hjiyiannakis D., Hines F., Traish D., Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys. 40:1998;1157-1162.
84. O'Brien, Roos D., Pratt G., et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 18:2001;519-526.
85. Bessell E.M., Lopez-Guillermo A., Villa S., et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 20:2002;231-236.
86. Neuwelt E.A., Goldman D.L., Dahlborg S.A., et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive functions. J Clin Oncol. 9:1991;1580-1590.
87. Freilich R.J., Delattre J.Y., Monjour A., DeAngelis L.M. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 46:1996;435-439.
88. Sandor V., Stark-Vancs V., Pearson D., et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 16:1998;3000-3006.
89. Guha-Thakurta N., Damek D., Pollack C., Hochberg F. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life. J Neurooncol. 43:1999;259-268.
90. Schlegel U., Pels H., Glasmacher A., et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry. 71:2001;118-122.
91. Bessell E.M., Graus F., Lopez-Guillermo A., et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 50:2001;457-464.
92. Abrey L.E., DeAngelis L.M., Yahalom J. Long term survival in primary central nervous system lymphoma. J Clin Oncol. 16:1998;859-863.
93. Abrey L.E., Yahalom J., DeAngelis L.M. Treatment of primary CNS lymphoma: the next step. J Clin Oncol. 18:2000;3144-3150.
94. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or first relapse primary central nervous system lymphoma or intraocular lymphoma. J Clin Oncol. 19:2000;742-749.
95. Reni M., Ferreri A.J., Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 79:1999;530-534.